Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lilja B Solnes

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Annals of Nuclear Medicine|August 24, 2017
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted <sup>18</sup>F-DCFPyL in peripheral gangliaRudolf A Werner, Sara Sheikhbahaei, Krystyna M Jones, et al.
Nuclear Medicine Communications|January 29, 2025
Lack of effect of renal function on uptake of 99m Tc-sestamibi in renal massesAlireza Amindarolzarbi, Kendall Satcowitz, Adham Khalil, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Phase 1 Study of [<sup>177</sup>Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry ResultsErik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
Clinical Nuclear Medicine|January 24, 2017
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal MassesSara Sheikhbahaei, Christopher S Jones, Kristin K Porter, et al.
Frontiers in Oncology|September 26, 2024
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinomaRajan Singh, Anand K Thotakura, Suresh Alati, et al.
Annals of Nuclear Medicine|March 1, 2023
Multi-timepoint imaging with PSMA-targeted [<sup>18</sup>F]F-Florastamin PET/CT: lesion detection and comparison to conventional imagingSara Sheikhbahaei, Ricardo Bello Martinez, Mark C Markowski, et al.
Journal of the American College of Radiology : JACR|March 20, 2026
ACR Appropriateness Criteria® Suspected and Known Renal or Splanchnic Artery Aneurysm, Sasan Partovi, Xin Li, et al.
The Journal of Urology|July 25, 2017
Prostate Specific Membrane Antigen Targeted <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center StudyMichael A Gorin, Steven P Rowe, Hiten D Patel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION DataVishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Annals of Nuclear Medicine|August 24, 2017
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted <sup>18</sup>F-DCFPyL in peripheral gangliaRudolf A Werner, Sara Sheikhbahaei, Krystyna M Jones, et al.
Nuclear Medicine Communications|January 29, 2025
Lack of effect of renal function on uptake of 99m Tc-sestamibi in renal massesAlireza Amindarolzarbi, Kendall Satcowitz, Adham Khalil, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Phase 1 Study of [<sup>177</sup>Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry ResultsErik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
Clinical Nuclear Medicine|January 24, 2017
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal MassesSara Sheikhbahaei, Christopher S Jones, Kristin K Porter, et al.
Frontiers in Oncology|September 26, 2024
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinomaRajan Singh, Anand K Thotakura, Suresh Alati, et al.
Annals of Nuclear Medicine|March 1, 2023
Multi-timepoint imaging with PSMA-targeted [<sup>18</sup>F]F-Florastamin PET/CT: lesion detection and comparison to conventional imagingSara Sheikhbahaei, Ricardo Bello Martinez, Mark C Markowski, et al.
Journal of the American College of Radiology : JACR|March 20, 2026
ACR Appropriateness Criteria® Suspected and Known Renal or Splanchnic Artery Aneurysm, Sasan Partovi, Xin Li, et al.
The Journal of Urology|July 25, 2017
Prostate Specific Membrane Antigen Targeted <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center StudyMichael A Gorin, Steven P Rowe, Hiten D Patel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION DataVishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Pageof 12